Evidence map›Paper›PMID 40703873›Full record

ArticleNigerian medical journal : journal of the Nigeria Medical Association

Clinical Challenges with Neovascular Glaucoma-Patient Tailored Strategies and Outcomes.

Aparna Rao, Tapas Ranjan Padhi, Sanjib M Khan

Abstract read
In one paragraph

Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Research Progress of Diabetes-related Glaucoma: Mechanisms, Impacts and Management Strategies.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aparna RaoGlaucoma Service, LV Prasad Eye Institute, Kallam Anji Reddy campus, Hyderabad, India.
Tapas Ranjan PadhiGlaucoma Service, LV Prasad Eye Institute, Kallam Anji Reddy campus, Hyderabad, India.
Sanjib M KhanGlaucoma Service, LV Prasad Eye Institute, Kallam Anji Reddy campus, Hyderabad, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To report the outcomes of patient-tailored concurrent combined surgery for retinal ischemia and intraocular pressure (IOP) control in neovascular glaucoma (NVG) with or without cataract. Methodology: Patients with Ninety-seven (97) eyes with NVG seen between January 2022-September 2023 at a tertiary eye care centre were recruited for this study. Six (6) eyes (4 proliferative diabetic retinopathy and 2 retinal vein occlusions) that underwent concurrent retinal and glaucoma procedures with or without cataract surgery, were selected. Outcomes after surgery were judged based on the World Glaucoma Association guidelines on reporting glaucoma surgical trials, comprising functional and surgical parameters. Results: The IOP reduced by>50% from baseline in all 6 eyes, with one eye developing shallow AC by overstraining and 3 eyes developing transient self-resolving hyphema. Two eyes received additional bevacizumab (n=1) or ranibizumab (n=1) injections for persistent DME at 4 and 5 months after surgery. The final IOP was reduced in all eyes at the final follow-up of 6±1.2 months, with one eye requiring 2 medications for IOP control. Conclusion: The outcomes after concurrent retinal and glaucoma filtering surgery in NVG may be comparable to those of the traditional stepwise approach to management, provided these are offered on a case-by-case basis.

Indexed as

IOPNeovascular GlaucomaRetinal IschemiaSurgical OutcomesVEGF

Identifiers

PMID40703873
PMCPMC12280322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.